EN | FR

EN | FR

Navigation Request a Free Trainer
Widely available across Canada.

EXPERTLY DESIGNED

DOWN TO THE SMALLEST DETAIL1,2

ALLERJECT is an epinephrine auto-injector that’s designed to be portable,* to assist patients with life-threatening allergies in complying with recommendations that epinephrine should be available at all times.

* ALLERJECT device is 8.5 cm long and 5.4 cm wide.

EXPERTLY DESIGNED

DOWN TO THE SMALLEST DETAIL1,2

ALLERJECT has built-in voice instructions designed to assist patients in administering epinephrine without delay.

EXPERTLY DESIGNED

DOWN TO THE SMALLEST DETAIL1,2

ALLERJECT is designed with a retractable needle system to mitigate use-related hazards.1

Register for updates about ALLERJECT
and order a free trainer device.

SIGN UP NOW

AVAILABLE IN TWO DOSES

A 0.15 mg ALLERJECT device next to a 0.3 mg ALLERJECT device.

ALLERJECT 0.15 mg

Intended for patients who
weigh 15 to 30 kg

ALLERJECT 0.3 mg

Intended for patients who
weigh 30 kg or more

DESIGNED WITH YOUR PATIENTS IN MIND

With step-by-step voice assistance, ALLERJECT guides users through the injection process.

DOWNLOAD
INSTRUCTIONS-FOR-USE VIDEO

ABOUT KALÉO

Our company is purposefully driven by patient‑inspired design.

Each component and device is assembled through a quality‑driven manufacturing process.

  • A 100% automated robotic production line
  • Over 100 automated quality checks on each device
  • Specially calibrated sensors and vision inspection systems2

IMPORTANT SAFETY INFORMATION1

Indications and clinical use:

ALLERJECT 0.3 mg (0.3 mL epinephrine injection, USP) and ALLERJECT 0.15 mg (0.15 mL epinephrine injection, USP) are indicated for the emergency treatment of anaphylactic reactions in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight. ALLERJECT is intended for immediate self‑administration for the emergency treatment of severe allergic reactions (Type I). Following treatment of anaphylaxis, the patient must seek immediate medical attention.

Contraindications:

No absolute contraindications.

Relevant warnings and precautions:

  • In conjunction with administration, patients should seek appropriate medical care
  • More than two sequential doses of epinephrine should only be administered under direct medical supervision
  • Only inject into the outer thigh
  • Caregivers should hold the leg of young children firmly in place and limit movement prior to and during injection
  • Rare cases of serious infections at the injection site have been reported
  • Avoid use in patients with cardiogenic, traumatic or hemorrhagic shock, cardiac dilation, cerebral arteriosclerosis; use with caution in patients with cardiac arrhythmias, coronary artery or organic heart disease, hypertension or hyperthyroidism
  • Use with caution in patients with diabetes
  • Avoid use in patients with organic brain damage; use with caution in patients with Parkinson’s disease
  • Avoid use in patients with narrow‑angle glaucoma
  • Use with caution in patients with concomitant asthma
  • Use with caution in patients with sulfite sensitivity

For more information:

Please consult the Product Monograph at Allerject.ca/PM for important information relating to adverse reactions, drug interactions and dosing information which has not been discussed in this piece. The Product Monograph is also available by calling us at 1‑888‑680‑7340.

† Clinical significance is unknown.

References: 1. ALLERJECT Product Monograph. kaleo, Inc. November 21, 2019. 2. Data on file.